AI
| Followers | 843 |
| Posts | 122817 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Tuesday, December 16, 2003 10:35:59 AM
From the same OXGN patent:
>>
[0141] Topical gels and solutions were developed for use as topical formulation suitable for the topical delivery of CA4P to the surface of the eye. Topical solutions (1, 3, and 10%) were directly prepared in 0.9% NaCl (Aguettant, Lyon, France) and sterilized with 0.2 um filter (pH 6.4 to 8.5, osmolarity 290 to 459 mosmol/kg H.sub.2O. Low viscosity topical gels (1,3,and 10%) were prepared in 0.5% carboxymethylcellulose (Sigma Aldrich Chimie, St. Quentin Fallavier Cedex, France) with 0.9% NaCl.
<<
--
isolution: A little birdie tells me that you may be familiar with this work
Are you aware of any conflicting or overlapping patents held by AVE, AZN, or other companies in the use of VTA’s in eye diseases? T.i.a.
>>
[0141] Topical gels and solutions were developed for use as topical formulation suitable for the topical delivery of CA4P to the surface of the eye. Topical solutions (1, 3, and 10%) were directly prepared in 0.9% NaCl (Aguettant, Lyon, France) and sterilized with 0.2 um filter (pH 6.4 to 8.5, osmolarity 290 to 459 mosmol/kg H.sub.2O. Low viscosity topical gels (1,3,and 10%) were prepared in 0.5% carboxymethylcellulose (Sigma Aldrich Chimie, St. Quentin Fallavier Cedex, France) with 0.9% NaCl.
<<
--
isolution: A little birdie tells me that you may be familiar with this work
Are you aware of any conflicting or overlapping patents held by AVE, AZN, or other companies in the use of VTA’s in eye diseases? T.i.a.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
